Private equity moves deeper into biotech royalties as funding crisis intensifies
Private equity firms deployed $5.42 billion into biotech and pharmaceutical royalty transactions through 2025, marking a 7% increase from
The weekly term sheet (33)
Pharma & biotech deals heat up with $5B+ in transactions
The week of August 11-15, 2025 witnessed a striking bifurcation
Space: the final formulation frontier
These are the voyages of a new class of pharmaceutical pioneers.
Their five-year mission: to explore strange crystallization conditions,
to
Company of the week: Arrakis navigates the undruggable desert
Finding the spice in RNA's vast landscape
Arrakis Therapeutics has positioned itself as a pioneer in RNA-targeted small
Fund of the week: RTW Investments
RTW Investments has transformed from a specialized healthcare hedge fund into a $9.8 billion life sciences investment platform that
Advanced Private Equity Deal Structuring in Biotech & Pharma (U.S. & Europe)
Risk-Adjusted NPV (rNPV) in Biotech Valuation
The rNPV Formula
rNPV = Σ [P(success) × NPV(success) + P(fail) × NPV(fail)]
Explicitly
Regulatory Sandboxes for AI in Drug Development and Clinical Trials
Regulator
Depth/Specificity of AI Sandbox
(focus on AI in drug development)
Scope of AI Experimentation
(breadth of permitted AI
Special Purpose Acquisition Companies in Healthcare and Biotech: A Mid-2025 Market Appraisal
The landscape for Special Purpose Acquisition Companies (SPACs) within the healthcare and biotechnology sectors in mid-2025 presents a complex, dual
The weekly term sheet (32)
Global pharmaceutical and biotech deals remain subdued during August week
The week of August 4-9, 2025 marked an unusually quiet
The great AI medicine show
In the late 19th century, traveling medicine shows peddled cure-all elixirs with flamboyant claims. Today’s equivalent in biotech is
